Breaking News
February 24, 2019 - Novel MRI sensor can peer deep into the brain to detect intracellular calcium activity
February 24, 2019 - AHA News: Diabetes Remains Dangerous Despite Modern Medicine
February 24, 2019 - Dup15q syndrome – Genetics Home Reference
February 24, 2019 - Could ‘Cardio-obstetrics’ curb rise in pregnancy-related deaths?
February 24, 2019 - Using computer model to visualize brain’s internal valuation system
February 24, 2019 - Study reveals insights into how the brain learns new locomotor patterns
February 24, 2019 - Depression Screening: MedlinePlus Lab Test Information
February 24, 2019 - Researchers discover a weakness in a rare cancer that could be exploited with drugs
February 23, 2019 - U.S.-based patient advocacy organizations received majority of pharma donations, finds study
February 23, 2019 - UCL and AIIMS collaborates to increase academic and student exchange
February 23, 2019 - Mechanism behind how diabetes causes muscle loss revealed
February 23, 2019 - Hepatocellular carcinoma diagnosis, prognosis and treatment may improve by identifying a protein
February 23, 2019 - The American Heart Association issues new reference toolkit for healthcare providers
February 23, 2019 - Studies explore physiological dangers that climate change will have on animal life
February 23, 2019 - Penn study reveals increase in health-related internet searches before ER visits
February 23, 2019 - Intensive therapy during early stages of MS leads to better long-term outcomes
February 23, 2019 - Prenatal Fluconazole Exposure Increases Neonatal Risks
February 23, 2019 - Mental Health Screening: MedlinePlus Lab Test Information
February 23, 2019 - Study suggests birth mechanics are part of the process that leads to autism
February 23, 2019 - Unhealthy diet linked to poor mental health
February 23, 2019 - Study gives a snapshot of crocodile evolution
February 23, 2019 - Research finds steep rise in self-poisonings among young people
February 23, 2019 - American Gastroenterological Association announces “AGA Future Leaders Program”
February 23, 2019 - Scientists uncover new mechanisms regulating neural stem cells
February 23, 2019 - Combinations of certain insecticides turn out to be lethal for honeybees
February 23, 2019 - AHA News: Why Are Black Women at Higher Risk of Dying From Pregnancy Complications?
February 23, 2019 - NIMH » Anxiety Disorders
February 23, 2019 - Autistic people urgently need access to tailored mental health support
February 23, 2019 - Newly designed molecule could benefit people with Friedrich’s Ataxia
February 23, 2019 - Chinese CRISPR twins may have better cognition and memory
February 23, 2019 - Study finds new genetic clues associated with asthma in African ancestry populations
February 23, 2019 - Fetal signaling pathways may offer future opportunities to treat lung damage
February 23, 2019 - Early-stage osteoarthritis drug wins prestigious innovation award
February 23, 2019 - Researchers report positive findings with dasotraline for ADHD in children ages 6-12
February 23, 2019 - News study reanalyzes the effects of noncaloric sweeteners on gut microbiota
February 23, 2019 - New device allows scientists to reproduce blow effects on the heart in lab
February 23, 2019 - Paying more attention to antibiotic dosing could improve clinical outcomes for CF patients
February 23, 2019 - Big-data analysis finds new link between popular arthritis drug and heart valve calcification
February 23, 2019 - Holy herb identified as a potential treatment for Alzheimer’s disease
February 23, 2019 - New technology platform digitally counts growth factors in single cells
February 23, 2019 - Physicians still remain at higher risk for burnout compared to other professionals
February 23, 2019 - Surgery and other treatments offer viable options for adult scoliosis
February 23, 2019 - Reduced antibody adaptability may make the elderly more vulnerable to influenza
February 23, 2019 - Researchers find increased rates of CRC screening in Kentucky after Medicaid expansion
February 23, 2019 - Neighborhood income, education associated with risk of disability progression in MS patients
February 23, 2019 - Endocrine Society opposes new rule that restricts access to Title X Family Planning Program
February 23, 2019 - 2019 guidelines for management of patients with atrial fibrillation
February 23, 2019 - Surprise rheumatoid arthritis discovery points to new treatment for joint inflammation
February 23, 2019 - A just-right fix for a tiny heart
February 23, 2019 - UMass Amherst scientist explores role of citrus peel in decreasing gut inflammation
February 23, 2019 - Owlstone Medical and Shanghai Renji Hospital collaborate to initiate breath biopsy lung cancer trial
February 23, 2019 - AMSBIO’s comprehensive portfolio of knock-out cell lines and lysates
February 23, 2019 - New app reliably determines physicians’ skills in forming accurate, efficient diagnoses
February 23, 2019 - Peripheral nerve injury can trigger the onset and spread of ALS, shows study
February 23, 2019 - Researchers uncover mechanisms that prevent tooth replacement in mice
February 23, 2019 - Once-a-day capsule offers new way to reduce symptoms of chronic breathlessness
February 23, 2019 - FDA Adds Boxed Warning for Increased Risk of Death with Gout Medicine Uloric (febuxostat)
February 23, 2019 - Phone-based intervention aids rheumatoid arthritis care
February 23, 2019 - Opioid epidemic makes eastern inroads and targets African-Americans
February 23, 2019 - New identified biomarker predicts patients who might benefit from HER2-targeted agents
February 23, 2019 - Study offers new insights into mechanisms of changes in erythrocytes under stress
February 23, 2019 - Antipsychotic polypharmacy may be beneficial for schizophrenia patients
February 23, 2019 - Researchers investigate how marijuana and tobacco co-use affects quit attempts by smokers
February 23, 2019 - Patients with diabetes mellitus have high risk of stable ischemic heart disease
February 23, 2019 - Transparency on healthcare prices played key role in Arizona health system’s turnaround
February 23, 2019 - A comprehensive, multinational review of peppers around the world
February 23, 2019 - Study finds modest decrease in burnout among physicians
February 23, 2019 - A simple change can drastically reduce unnecessary tests for urinary tract infections
February 23, 2019 - Deep Learning-Enhanced Device Detects Diabetic Retinopathy
February 23, 2019 - Researchers discover new binding partner for amyloid precursor protein
February 23, 2019 - Modest decrease seen in burnout among physicians, researchers say | News Center
February 23, 2019 - Transplanting bone marrow of young mice into old mice prevents cognitive decline
February 23, 2019 - Mogrify to accelerate novel IP and cell therapies using $3.7m USD funding
February 23, 2019 - Johns Hopkins study describes cells that may help speed bone repair
February 23, 2019 - Scientists demonstrate influence of food odors on proteostasis
February 23, 2019 - Researchers unlock the secret behind reproduction of fish called ‘Mary’
February 23, 2019 - Acupuncture Could Help Ease Menopausal Symptoms
February 23, 2019 - Researchers use AI to detect early signs of Alzheimer’s
February 23, 2019 - On recovery, vulnerability and ritual: An exhibit in white | News Center
February 23, 2019 - Memory Stored in Unexpected Region of the Brain
Unique mechanism of action inhibiting paracellular phosphate absorption

Unique mechanism of action inhibiting paracellular phosphate absorption

image_pdfDownload PDFimage_print
Credit: CC0 Public Domain

Ardelyx, Inc. today announced that the novel mechanism of action for tenapanor for the treatment of hyperphosphatemia, or elevated serum phosphorus, has been published in the peer-reviewed journal Science Translational Medicine. Tenapanor is a sodium/hydrogen exchanger 3 (NHE3) inhibitor currently being evaluated in a second Phase 3 registration trial, the PHREEDOM trial, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) who are on dialysis. The paper, titled “Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability,” can be accessed in the current online edition of the publication.

“The elucidation of tenapanor’s mechanism is a landmark discovery in our field, causing us to completely rethink our understanding of phosphate transport and absorption,” said Geoff Block, M.D., director of clinical research at Denver Nephrology Research, and a PHREEDOM trial investigator. “Nearly all patients with ESRD have elevated serum phosphorus, a problem that if not managed properly through diet changes and prescription medication, can lead to an increase in morbidity and mortality in patients. Today, our only therapeutic option is to use phosphate binders, which are inadequate in reducing serum phosphorus in the majority of patients and associated with a number of challenges, including low rates of compliance because of the large number of pills that must be taken each day, significant tolerability issues and long-term concerns related to the safety of our patients. I believe tenapanor could shift our treatment approach and offer a significant benefit to patients, who absolutely need better options.”

Ardelyx scientists, in collaboration with global academic experts, established the mechanism by which tenapanor reduces gastrointestinal phosphate absorption using in vivo studies in rodents, as well as Ardelyx’s human stem cell-based translational technology called the Ardelyx Primary Enterocyte and Colonocyte Culture System (APECCS). In the past, the literature has described two pathways of phosphate absorption in the gut: active transcellular transport directly through the cells lining the gut and passive paracellular flux through tight junction protein pores between cells. Historically, the science has focused almost exclusively on the transcellular transport pathway where specific transporter proteins bring phosphate into and through intestinal cells and into the blood. Ardelyx’s discoveries conclude that phosphate absorption in humans actually occurs primarily through a dynamically regulated paracellular pathway. This pathway of phosphate flux is inhibited by tenapanor in a manner that appears largely specific for phosphate, whereas the overall absorption of other ions and large molecules appear not to be affected. Tenapanor’s phosphate mechanism is due to its direct action on NHE3, which exchanges sodium from the lumen of the gut for an intracellular proton. Inhibition of NHE3 by tenapanor results in proton retention in the cell, which modulates tight junction proteins to decrease permeability to phosphate, reducing paracellular phosphate absorption. Dynamic regulation of the permeability characteristics of the tight junction pore has only very recently been recognized, and tenapanor is the first agent to demonstrate this dynamic regulation of paracellular phosphate permeability.

Tenapanor’s novel mechanism of action has translated into meaningful reductions in serum phosphorus in humans, as reported in the findings from Ardelyx’s first Phase 3 clinical study evaluating tenapanor for the treatment of hyperphosphatemia in ESRD patients on dialysis. That trial met its primary endpoint, demonstrating a statistically significant difference in change in serum phosphorus between pooled tenapanor-treated patients and placebo-treated patients from the end of the eight-week treatment period to the end of the four-week randomized withdrawal period, in the responder population. Tenapanor was also well-tolerated in the trial, with limited discontinuations due to GI-related adverse events in the treatment period and no discontinuations related to GI events in the randomized withdrawal period.

“Tenapanor’s dynamic mechanism of lowering phosphate by tight junction modulation with just two small pills has the potential to offer a first-of-its-kind approach to treating this large and growing patient population,” commented David Rosenbaum, Ph.D., chief development officer of Ardelyx. “This important publication showcases our commitment to scientific innovation, unique insights into the biology of the gut and chemistry capabilities that enable us to design and optimize gut-restricted compounds. Tenapanor, if approved, would offer an entirely new way of treating ESRD patients who need a convenient, effective and tolerable medicine for managing phosphorus.”

Ardelyx’s Phase 3 PHREEDOM trial is enrolling patients, and the company expects to report results from this registration study in 2019.

About hyperphosphatemia

Phosphorus, a vital element required for most cellular processes, is present in almost every food in the Western diet, and, in individuals with normal kidney function, excess dietary phosphorus is efficiently removed by the kidneys and excreted in urine. In adults with functioning kidneys, normal serum phosphorus levels are 2.5 to 4.5 mg/dL. With kidney failure, elevated phosphorus becomes harmful and is diagnosed as hyperphosphatemia when serum phosphorus levels are greater than 4.5 mg/dL, according to KDIGO guidelines1. Although patients with end-stage renal disease (ESRD) rely on dialysis to eliminate harmful agents, these patients cannot adequately handle a typical daily phosphate intake and other means of managing phosphorus levels must be employed. In addition to dialysis, ESRD patients are put on restrictive low phosphorus diets and are currently prescribed medications called phosphate binders, the only interventions currently marketed for the treatment of hyperphosphatemia.


Explore further:
Study questions safety and effectiveness of common kidney disease drugs

More information:
Andrew J. King et al. Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability, Science Translational Medicine (2018). DOI: 10.1126/scitranslmed.aam6474

Journal reference:
Science Translational Medicine

Provided by:
Ardelyx

About author

Related Articles